Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 131Colonic Neoplasms 72Rectal Neoplasms 61Breast Neoplasms 61Stomach Neoplasms 37Pancreatic Neoplasms 31Squamous Cell Carcinoma of Head and Neck 27Esophageal Neoplasms 24Head and Neck Neoplasms 23Neoplasm Metastasis 22Esophageal Squamous Cell Carcinoma 16Carcinoma, Hepatocellular 16Adenocarcinoma Of Esophagus 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Neoplasms 11Nasopharyngeal Carcinoma 11Adenocarcinoma 7Urinary Bladder Neoplasms 5Keratosis, Actinic 5Cholangiocarcinoma 5Anus Neoplasms 5Intestinal Neoplasms 4Inflammatory Breast Neoplasms 4Hepatoblastoma 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Biliary Tract Neoplasms 4Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3HIV Infections 3

Interventions

Docetaxel 3Cyclophosphamide 3Paclitaxel 2Epirubicin 2Tamoxifen 1Fluorouracil 1Doxorubicin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Primary Breast Cancer × Fluorouracil × Clear all
NCT04127019 2020-02-26

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Fudan University

Phase 3 Completed
2,079 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡